Health
Citing 'safety' and 'freedom,' HHS will allow compounding of certain wellness peptides
HHS on Wednesday said it will stop enforcing a ban on the compounding of certain popular peptides used for wellness purposes while the FDA works on rulemaking to address the substances. The federal agency released ...
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 36-word snippet. The full article is at the source.
More from Endpoints News and around the same time
AstraZeneca’s bruising summer raises the stakes for 2027When one of AstraZeneca’s medicines, Wainua, failed a major late-stage heart disease trial in July, it was a jarring setback for a drugmaker whose research pipeline had become one of the most admired in the ...Analysts press Biogen on lupus drug litifilimab ahead of pivotal readoutsScrutiny of Biogen’s late-stage pipeline is intensifying ahead of several Phase 3 readouts that are pivotal to CEO Chris Viehbacher's turnaround efforts. Analysts lobbed numerous questions at Viehbacher and other Biogen execs…Pfizer India site closure risks exacerbating cancer drug shortagesPfizer has been forced to temporarily close a cancer drug factory in India. The factory won’t reopen for up to two years and is already contributing to cancer drug shortages. In July, heavy monsoon rain ...Beijing-based BioGeometry gets $100M+ for AI drug R&DA Chinese biotech startup has raised more than $100 million in Series A funding for its AI-driven protein design. BioGeometry, a 4-year-old company headquartered in Beijing, said in a statement Wednesday ...Now 78% of scientists say AI will speed drug discovery this year: Signal SurveyA year ago, Endpoints Signal surveyed almost 1,500 biopharma insiders about the very near-term prospects of AI accelerating drug discovery. Scientists, interestingly, were the most skeptical. Now, as we revisit the question in ourLilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetesEli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabetes rather than obesity. The drug…This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
